Vanguard Group Inc. Has $24.14 Million Stock Holdings in Trevi Therapeutics, Inc. $TRVI

Key Points

• Vanguard Group Inc. increased its stake in Trevi Therapeutics by 9.4%, holding approximately 3.84% of the company's stock worth $24.14 million as of its recent SEC filing.
• Trevi Therapeutics shares fell by 9.9%, with the stock price opening at $7.21 and a market cap of $878.01 million.
• Analyst ratings for Trevi show a positive outlook, with an average rating of "Buy" and a consensus target price of $20.11.

Vanguard Group Inc. raised its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 9.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,838,032 shares of the company's stock after purchasing an additional 328,819 shares during the quarter. Vanguard Group Inc. owned about 3.84% of Trevi Therapeutics worth $24,141,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in TRVI. Raymond James Financial Inc. acquired a new position in Trevi Therapeutics during the fourth quarter valued at approximately $49,000. Squarepoint Ops LLC acquired a new position in Trevi Therapeutics during the fourth quarter valued at approximately $58,000. Two Sigma Advisers LP acquired a new position in Trevi Therapeutics during the fourth quarter valued at approximately $66,000. Cantor Fitzgerald L. P. acquired a new position in Trevi Therapeutics during the fourth quarter valued at approximately $82,000. Finally, ProShare Advisors LLC lifted its position in Trevi Therapeutics by 86.4% during the fourth quarter. ProShare Advisors LLC now owns 20,685 shares of the company's stock valued at $85,000 after buying an additional 9,589 shares in the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Oppenheimer reaffirmed an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Cantor Fitzgerald assumed coverage on Trevi Therapeutics in a research report on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 target price for the company. HC Wainwright initiated coverage on Trevi Therapeutics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price for the company. Finally, Morgan Stanley initiated coverage on Trevi Therapeutics in a research note on Thursday, August 21st. They issued an "overweight" rating and a $18.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $20.11.

Trevi Therapeutics Trading Up 0.7%

NASDAQ TRVI traded up $0.05 on Monday, hitting $7.26. 1,556,560 shares of the stock traded hands, compared to its average volume of 1,895,919. The stock has a 50-day moving average of $6.92 and a 200 day moving average of $6.30. Trevi Therapeutics, Inc. has a twelve month low of $2.36 and a twelve month high of $8.78. The company has a market capitalization of $884.10 million, a P/E ratio of -17.29 and a beta of 0.71.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. As a group, equities research analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.